| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.13 | 1e-05 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-05 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-05 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-05 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 1e-05 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-05 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | -0.14 | 2e-05 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.14 | 2e-05 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.24 | 2e-05 |